CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 19 enrolled
Drug / intervention
C-11 choline PET tracer +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03404648
NCT03404648Phase 3Completed
CompareCT.gov

Staging of Untreated Patients With Very High-risk and High-risk Prostate Carcinoma Utilizing Hybrid C11-choline PET/MR and Pelvic Multiparametric MRI for Personalized Precise Treatment: a Pilot Study

Mayo Clinic·interventional·Posted Jan 19, 2018·Updated Feb 8, 2021

In Brief

A Phase 3 clinical trial evaluating C-11 choline PET tracer, Gadobutrol, and 1 other intervention for Prostate Adenocarcinoma. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The purpose of this study is to find out if a PET/MR scan in combination with standard MRI and CT scans can improve the early detection and treatment of patients with prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Adenocarcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJan 19, 2018
Enrollment StartNov 1, 2017
Primary CompletionJan 23, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.5 years ago

Interventions

C-11 choline PET tracerdrug

C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.

Gadobutroldrug

Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.

PET/MR scannerdevice

C11-PET/MR and pelvic mpMRI scan for prostate cancer.